Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

Brain

Volumn 138, Issue 3, 2015, Pages 772-783

  Mattsson, Niklas ^a,b,c   Insel, Philip S ^b,c   Donohue, Michael ^d   Landau, Susan ^e   Jagust, William J ^e   Shaw, Leslie M ^f   Trojanowski, John Q ^f   Zetterberg, Henrik ^a,g   Blennow, Kaj ^a   Weiner, Michael W ^b,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid; Biomarker; Cerebrospinal fluid; Positron emission tomography

Indexed keywords

AMYLOID BETA PROTEIN; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE; TAU PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANILINE DERIVATIVE; APOLIPOPROTEIN E4; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; FLUORINE; FLUORODEOXYGLUCOSE F 18; PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; CEREBROSPINAL FLUID; COGNITION; CONTROLLED STUDY; DIAGNOSIS RELATED GROUP; DISEASE COURSE; FEMALE; HIPPOCAMPUS; HUMAN; INFORMATION; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; METABOLISM; MILD COGNITIVE IMPAIRMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM; COGNITION DISORDERS; COHORT ANALYSIS; COMPLICATION; DIAGNOSTIC USE; GENETICS; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; APOLIPOPROTEIN E4; COGNITION DISORDERS; COHORT STUDIES; ETHYLENE GLYCOLS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84927957367     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu367     Document Type: Article

References (57)

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-9.
2. Augutis K, Axelsson M, Portelius E, Brinkmalm G, Andreasson U, Gustavsson MK, et al. Cerebrospinal fluid biomarkers of b-amyloid metabolism in multiple sclerosis. Mult Scler 2013; 19: 543-52.
3. Bates D. lme4: Mixed-effects modeling with R. New York: Springer; 2010.
4. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605-13.
5. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-44.
6. Burnham KP, Anderson DR. Model Selection and Multimodal Inference. 2 edn. New York: Springer; 2002.
7. Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah A, et al. Absence of PIttsburgh compound B detection of cere-bralamyloid beta in a patient with clinical, cognitive, and cerebro-spinal fluidmarkers of alzheimer disease. Arch Neurol 2009; 66: 1557-62.
8. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305: 275-83.
9. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010; 67: 949-56.
10. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614-29.
11. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512-9.
12. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009; 1: 371-80.
13. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroana-tomical structures in the human brain. Neuron 2002; 33: 341-55.
14. Fischl B, van der Kouwe A, Destrieux C, Halgren E, Ségonne F, Salat DH, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004; 14: 11-22.
15. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456-65.
16. Friedman J, Hastie T, Tibshirani R. The elements of statistical learning. New York: Springer Series in Statistics; 2009.
17. Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, Mathis CA, et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebro-spinal fluid. Biol Psychiatry 2009; 65: 927-34.
18. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007; 23: 316-20.
19. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
20. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630-45.
21. Iliff JJ, Wang M, Zeppenfeld DM, Venkataraman A, Plog BA, Liao Y, et al. Cerebral arterial pulsation drives paravascular CSF-intersti-tial fluid exchange in the murine brain. J Neurosci 2013; 33: 18190-9.
22. Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27: 685-91.
23. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cog-nitively normal subjects. J Nucl Med 2012; 53: 378-384.
24. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004; 55: 306-19.
25. Koivunen J, Pirttilä T, Kemppainen N, Aalto S, Herukka S-K, Jauhianen AM, et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dementia and Geriatr Cogn Disord 2008; 26: 378-83.
26. 42in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. J Alzheimers Dis 2014; 41: 441-51.
27. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011; 32: 1207-18.
28. Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of b-amyloid. Ann Neurol 2013; 74: 826-36.
29. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012; 72: 578-86.
30. Leinenbach A, Pannee J, Dülffer T, Huber A, Bittner T, Andreasson U, et al. Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-b in cerebrospinal fluid. Clin Chem 2014; 60: 987-94.
31. Little R, Rubin D. Statistical analysis with missing data. 2 edn. Hoboken, New Jersey: Wiley; 2002.
32. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, et al. The Alzheimer's association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011; 7: 386-95, e6.
33. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 2013; 9: 251-261.
34. Mattsson N, Axelsson M, Haghighi S, Malmestrom C, Wu G, Anckarsater R, et al. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Mult Scler 2009; 15: 448-54.
35. Mattsson N, Bremell D, Anckarsater R, Blennow K, Anckarsater H, Zetterberg H, et al. Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neurol 2010; 10: 51.
36. Mattsson N, Insel PS, Landau S, Jagust W, Donohue M, Shaw LM, et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Ann Clin Transl Neurol 2014; 1: 534-43.
37. Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, Olsson M, et al. BACE1 Inhibition induces a specific cerebrospinal fluid beta-amyloid pattern that identifies drug effects in the central nervous system. PLoS One 2012; 7: e31084.
38. Mattsson N, Tosun D, Insel PS, Simonson A, Jack CR, Beckett LA, et al. Association of brain amyloid-b with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. Brain 2014; 137: 1550-61.
39. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, et al. Robust central reduction of amyloid-b in humans with an orally available, non-peptidic b-secretase inhibitor. J Neurosci 2011; 31: 16507-16.
40. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-9.
41. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005; 51: 336-45.
42. Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid b-Amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 2014; 71: 1282-1289.
43. Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, et al. Increased in vivo amyloid-b42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med 2013; 5: 189ra77.
44. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012; 11: 1048-1056.
45. Schmidt ML, DiDario AG, Lee VM, Trojanowski JQ. An extensive network of PHF tau-rich dystrophic neurites permeates neocortex and nearly all neuritic and diffuse amyloid plaques in Alzheimer disease. FEBS Lett 1994; 344: 69-73.
46. Schöll M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Langström B, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 2012; 79: 229-36.
47. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-13.
48. Slemmon JR, Meredith J, Guss V, Andreasson U, Andreasen N, Zetterberg H, et al. Measurement of Abeta1-42 in cerebrospinal fluid is influenced by matrix effects. J Neurochem 2012; 120: 325-33.
49. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-92.
50. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 2009; 50: 1464-70.
51. Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF Tau and Ab biomarkers for up to 48 months in ADNI. Acta Neuropathol 2013; 126: 659-70.
52. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 2011; 10: 241-52.
53. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid b deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013; 12: 357-67.
54. Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, et al. Transforming CSF A 42 measures into calculated Pittsburgh Compound B (PIBcalc) units of brain A amyloid. Alzheimers Dement 2011; 7: 133-41.
55. Wiltfang J, Esselmann H, Bibl M, Hüll M, Hampel H, Kessler H, et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low-and high-CSF A beta 40 load. J Neurochem 2007; 101: 1053-9.
56. Yamaguchi H, Nakazato Y, Hirai S, Shoji M, Harigaya Y. Electron micrograph of diffuse plaques. Initial stage of senile plaque formation in the Alzheimer brain. Am J Pathol 1989; 135: 593-7.
57. Zwan M, van Harten A, Ossenkoppele R, Bouwman F, Teunissen C, Adriaanse S, et al. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. J Alzheimers Dis 2014; 41: 801-7.